Hemophilia Care in India: A Review and Experience from a Tertiary Care Centre in Uttar Pradesh

被引:13
作者
Phadke, Shubha [1 ]
机构
[1] Sanjay Gandhi Postgrad Inst Med Sci, Dept Med Genet, Lucknow 226014, Uttar Pradesh, India
关键词
Hemophilia; Diagnosis; Inhibitors management; Bypassing agents; India; RECOMBINANT FACTOR VIIA; INHIBITOR DEVELOPMENT; HOME TREATMENT; RISK-FACTORS; MANAGEMENT; DIAGNOSIS; MULTICENTER; NOVOSEVEN; BLEEDS; AGENTS;
D O I
10.1007/s12288-011-0084-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Approximately 14,000 people with hemophilia are registered at the Hemophilia Federation of India; however, hemophilia remains under-diagnosed and many cases are not registered. In June 2009, the Government of Uttar Pradesh made anti-hemophilic factors available at a few centers, including the Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow. Consequently, the level of hemophilia care has improved considerably in recent times. Amongst the many challenges facing people with hemophilia, the development of inhibitors, which neutralize clotting factors provided by replacement therapy, is the most feared one. Healthcare professionals who treat people with hemophilia should not only be knowledgeable about the condition and committed to bettering the management of hemophilia, but also take responsibility for the judicious allocation of resources for various aspects of managing hemophilia. This manuscript aims to raise awareness regarding the detection and management of inhibitors in hemophilia based on the experience of a tertiary care hemophilia treatment centre in Uttar Pradesh, India.
引用
收藏
页码:121 / 126
页数:6
相关论文
共 40 条
[1]   Inhibitors in Hemophilia A: Advances in Elucidation of Inhibitory Mechanisms and in Inhibitor Management with Bypassing Agents [J].
Ananyeva, Natalya M. ;
Lee, Timothy K. ;
Jain, Nisha ;
Shima, Midori ;
Saenko, Evgueni L. .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2009, 35 (08) :735-751
[2]  
[Anonymous], FEIBA VH PRESCR INF
[3]   Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors [J].
Astermark, J. ;
Rocino, A. ;
Von Depka, M. ;
Van den Berg, H. M. ;
Gringeri, A. ;
Mantovani, L. G. ;
Morado, M. ;
Garrido, R. P. ;
Schiavoni, M. ;
Villar, A. ;
Windyga, J. .
HAEMOPHILIA, 2007, 13 (01) :38-45
[4]   Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report [J].
Astermark, J. ;
Altisent, C. ;
Batorova, A. ;
Diniz, M. J. ;
Gringeri, A. ;
Holme, P. A. ;
Karafoulidou, A. ;
Lopez-Fernandez, M. F. ;
Reipert, B. M. ;
Rocino, A. ;
Schiavoni, M. ;
von Depka, M. ;
Windyga, J. ;
Fijnvandraat, K. .
HAEMOPHILIA, 2010, 16 (05) :747-766
[5]   A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study [J].
Astermark, Jan ;
Donfield, Sharyne M. ;
DiMichele, Donna M. ;
Gringeri, Alessandro ;
Gilbert, Steven A. ;
Waters, Jennifer ;
Berntorp, Erik .
BLOOD, 2007, 109 (02) :546-551
[6]   International workshop on immune tolerance induction: consensus recommendations [J].
Dimichele, D. M. ;
Hoots, W. K. ;
Pipe, S. W. ;
Rivard, G. E. ;
Santagostino, E. .
HAEMOPHILIA, 2007, 13 :1-22
[7]   Comprehensive care for haemophilia around the world [J].
Evatt, BL ;
Black, C ;
Batorova, A ;
Street, A ;
Srivastava, A .
HAEMOPHILIA, 2004, 10 :9-13
[8]  
EWING NP, 1982, AM J CLIN PATHOL, V77, P749
[9]   Management of haemophilia and its complications in developing countries [J].
Ghosh, K .
CLINICAL AND LABORATORY HAEMATOLOGY, 2004, 26 (04) :243-251
[10]   First-time development of FVIII inhibitor in haemophilia patients during the postoperative period [J].
Ghosh, K ;
Jijina, F ;
Shetty, S ;
Madkaikar, M ;
Mohanty, D .
HAEMOPHILIA, 2002, 8 (06) :776-780